Core Viewpoint - The stock of Insilico Medicine (03696) rose over 10% following the announcement of a milestone payment from Menarini Group after the completion of the first patient dosing in the Phase I clinical trial of MEN2501, a KIF18A inhibitor designed for treating chromosomal instability solid tumors [1] Group 1: Company Developments - Insilico Medicine received a milestone payment of HKD 39 million from Menarini Group after the first patient dosing in the MEN2501 project [1] - This follows a previous milestone payment of over HKD 23.4 million received in July 2025 for development and regulatory milestones [1] - MEN2501 is a highly differentiated KIF18A inhibitor designed using Insilico's generative AI engine [1] Group 2: Industry Insights - Morgan Stanley's report highlights Insilico Medicine as a leader in the AIDD (AI-Driven Drug Discovery) field, noting substantial progress in both technology validation and application [1] - The execution capability of its chemical models supports a repeatable "1-to-N" innovation creation engine [1] - As biological model human validation becomes more evident, the potential upside for the company is expected to be further released as the industry enters a broader adoption phase of AIDD [1]

Core Viewpoint - The development of fixed asset investment in China has reached an advanced stage, leading to an urgent demand for high-level human capital, emphasizing the need for a synergy between investment in physical and human capital to overcome current investment growth bottlenecks [1] Group 1: Constraints on Investment Growth - Insufficient accumulation of human capital has become a significant bottleneck for enhancing the effectiveness of fixed asset investment, as the increasing technological and knowledge intensity of investments requires high-quality human capital [2] - The technical content of assets formed by fixed asset investment has significantly increased, necessitating higher professional capabilities from users, which is evident in advanced projects like the Shanghai Tesla Gigafactory [2] - The demand for professional talent is critical in maintaining the operational efficiency of high-tech assets, as a lack of skilled personnel can lead to resource wastage and hinder investment effectiveness [2] Group 2: Consumer Technology Literacy - The technological attributes of end products and services from fixed asset investments are increasing, which raises the requirement for consumer technology literacy [3] - In 2025, China's sales of new energy vehicles reached 14.78 million units, indicating that consumer understanding of smart technologies is essential for fully realizing the benefits of high-tech products [3] - Insufficient consumer technology literacy can suppress demand for high-tech products, affecting the efficiency of fixed asset investment cycles and limiting domestic demand potential [3] Group 3: Human Capital Demand in Investment Activities - Investment activities, especially in emerging and future industries, require deep involvement from specialized technical talent at every stage, from planning to operation management [4] - New fixed assets that incorporate new technologies have a higher relative demand for skilled labor, and a lack of high-quality professionals can significantly reduce the quality and long-term returns of fixed asset investments [4] Group 4: Pathways to Overcome Human Capital Constraints - The synergy between investment in physical and human capital is essential for breaking through development bottlenecks and maximizing investment effectiveness [5] - Investment in human capital should focus on enhancing professional capabilities to match the high demands of technological assets, ensuring that labor force skills align with investment needs [5] Group 5: Key Tasks for Investing in Human Capital - The strategy for investing in human capital should focus on education, employment, and industrial policies to promote deep integration between human and physical capital [9] - In the education sector, fostering cultural and scientific literacy among youth is crucial, with initiatives like industry-education integration proving effective in addressing human capital gaps [9] - In the employment sector, reforming research systems to release innovation potential and aligning talent with industry needs is vital for enhancing investment quality [10] - Industrial policies should facilitate the alignment of human capital supply with industry demand, promoting a virtuous cycle of investment in human capital leading to industrial upgrades and enhanced investment returns [10]

Group 1 - Garden Biologics experienced a decline of 5.22% on February 9, with a stock price of 18.15 yuan per share and a trading volume of 585 million yuan, resulting in a turnover rate of 5.88% and a total market capitalization of 9.864 billion yuan [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Among the top circulating shareholders of Garden Biologics, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which accounts for 0.65% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF (512100) today is approximately 3.4785 million yuan. The fund was established on September 29, 2016, with a latest scale of 78.996 billion yuan, and has achieved a 6% return this year, ranking 1533 out of 5580 in its category [2] - The fund manager, Cui Lei, has a tenure of 7 years and 96 days, with a total fund asset size of 137.02 billion yuan. The best fund return during the tenure is 279.97%, while the worst return is -15.93% [2]

这提示了我们，癌症免疫治疗中可能存在着一种 内在随机性 ，这意味着，即使我们将来对所有已知的确定性机制都了如指掌，这种内在随机性为癌症免疫疗法的 成功设定了一个理论上限，导致我们无法完全预测治疗结局。 2026 年 2 月 5 日，美国国家癌症研究中心的研究人员在国际顶尖学术期刊 Cell 上发表了题为： Stochasticity in cancer immunotherapy stems from rare but 撰文丨王聪 编辑丨王多鱼 排版丨水成文 functionally critical Spark T cells 的研究论文。 癌症免疫疗法这一不断扩大的领域，很大程度上得益于过继 T 细胞疗法和/或检查点抑制疗法在一小部分传统疗法 （放疗、化疗和手术） 无效癌症患者身上取得 的成功。然而，大多数癌症患者对癌症免疫疗法仍无良好响应，这可能是由于肿瘤细胞的遗传或表观遗传改变、环境因素、缺乏适当的肿瘤特异性 T 细胞以及肿 瘤浸润淋巴细胞 （TIL） 的耗竭表型所致。所有这些因素都是决定性的，这意味着对这些机制有更深入的理解应该足以准确预测每位患者对癌症免疫疗法的响应 或抵抗情况。 该研究表明，癌症 ...

| 地区 | 2026产业布局 | | --- | --- | | 广东 | 未来产业:第六代移动通信、量子科技、细胞与基因治疗、脑科学与脑机接口、氢能 及先进核能、深海探测、具身智能新兴产业:种业和种畜禽、海洋油气、商业航天(卫 | | | 星研发制造、火箭总装测试、卫星数据应用)、低空经济、绿色核能、游戏出海、数 | | | 智加工、跨境电商直播 | | 江苏 | 未来产业:深海空天、生物医药、脑机接口、量子科技 | | 山东 | 新兴支柱产业:人工智能(机器人和智能装备)、生物医药、新能源汽车(机电电控、 | | | 智能网联)、航空航天(火箭、卫星制造、航天配套)与低空经济 | | 浙江 | 新兴支柱产业:新材料、新能源、集成电路、航空航天、低空经济、生物医药、视觉 健康 | | 四川 | 优势矿产资源深加工、新能源新材料、先进核电:算力、数据、人工智能、电子信息 "四大产业"、先进装备、航空航天及电子(低空飞行器制造、低空动力系统、航空机 载零部件等产业)、矿山机械、应急救援、文体康旅、山地农业等专用装备及配套产 | | | 业、生物制造、具身智能创新药研发、新型疫苗、血液制品、活体、干细胞等生物技 ...

中金发表研报指，信达生物预告去年全年产品收入约119亿元，年增约45%，其中第四季度产品收入约 33亿元，年增超过60%，符合中金预期。由于四季度公司计提了六款首次纳入2026年医保目录新产品的 库存补差，预计剔除该影响，公司四季度实际收入将体现更明显增长，略超中金预期，主要得益于新品 放量。考虑到2026武田合作款影响，上调2026年归母净利润预测274%至66.8亿元，并引入2027年归母 净利润预测41.4亿元。该行维持对其"跑赢行业"评级，基于DCF模型维持目标价118.3港元不变。 ...

Core Insights - The Hong Kong IPO market is experiencing a significant transformation focused on quality, with regulatory bodies emphasizing the need for improved standards amidst a surge in new listings and fundraising [1][3][4] Group 1: Market Performance - As of February 8, 2026, the Hong Kong IPO market has seen 18 new listings, a year-on-year increase of 125%, with total fundraising reaching 67.55 billion HKD, a staggering increase of 1029.23% [1] - New economy sectors such as AI, semiconductors, and renewable energy are prominently represented, with over 60% of the 550 companies that filed for IPOs in 2026 coming from these fields [4] Group 2: Regulatory Changes - The Hong Kong Securities and Futures Commission has adopted a "zero tolerance" approach, halting the review of 16 problematic applications to ensure compliance and quality [3][4] - New regulatory measures include a quality assessment mechanism and stricter responsibilities for sponsors, ensuring that they thoroughly verify the accuracy of prospectus data [7][8] Group 3: Market Structure and Future Outlook - The "A+H" listing model is becoming more prevalent, with five A-share companies successfully listing in Hong Kong in 2026, indicating a shift towards a more integrated market structure [5] - Future innovations may include a "sandbox regulatory" approach to provide more flexible listing paths for tech companies, enhancing the overall market environment [6][9] - The introduction of advanced technologies like blockchain and AI is expected to improve the efficiency of the review process, making it more streamlined and effective [9]

2月9日，2026年江苏省政府工作报告全文发布。 今年经济社会发展主要预期目标是：地区生产总值按增长5%安排，在实际工作中努力争取更好结果； 一般公共预算收入增长2%；城镇新增就业120万人，城镇调查失业率5%左右；居民消费价格涨幅2%左 右；居民收入增长与经济增长同步；社会消费品零售总额增长5%左右；全社会研发投入强度3.42%左 右；粮食产量保持稳定；单位地区生产总值二氧化碳排放降低完成国家下达任务。 深入实施培育发展未来产业三年行动，健全投入增长和风险分担机制，支持原创性、颠覆性技术项目， 培育发展量子科技、生物制造、氢能、脑机接口、具身智能、第六代移动通信等前沿性未来产业，争创 国家未来产业先导区。 根据资源禀赋、产业基础、科研条件等，有选择地培育发展未来产业，防止脱离实际、一哄而上。 加快扬子江城市群建设，推动苏锡常、宁镇扬、锡常泰等融合发展，支持江淮生态经济区发展优势产业 和富民产业，提升徐州区域中心城市能级。 推进北沿江、通苏嘉甬等高铁建设，积极谋划沿海高铁通道建设，建成江阴靖江等过江通道，实施连云 港徐圩港区疏港航道等项目，打造"水运江苏"现代化水网和高等级航道网，加快南京机场三期、南通新 机 ...

Economic Performance - Shanghai's GDP reached 5.67 trillion yuan, growing by 5.4%, exceeding expectations [5] - The city's general public budget revenue was 850 billion yuan, an increase of 1.5% [5] - The average urban unemployment rate was 4.2% [5] Innovation and Industry Development - R&D expenditure accounted for approximately 4.5% of GDP [5] - The total output value of strategic emerging industries grew by 6.5%, making up 45% of the industrial output [5] - The three leading industries—integrated circuits, biomedicine, and artificial intelligence—surpassed 2 trillion yuan in scale [5] Foreign Trade and Investment - Total foreign trade reached 4.51 trillion yuan, with exports increasing by 10.8% [5] - Actual foreign investment was 16.06 billion USD, equivalent to 114.8 billion yuan [5] - The number of foreign-funded regional headquarters and R&D centers accelerated [5] Social Welfare and Living Standards - Per capita disposable income reached 92,000 yuan, growing by 4.1% [5] - PM2.5 annual average concentration decreased by 7.4% to 26.3 micrograms per cubic meter [5] - The city added 127 parks, achieving a total of 1,100 parks, with 89.4% open 24 hours [5] Urban Development and Infrastructure - Major engineering investments totaled 251 billion yuan, with fixed asset investment growing by 4.6% [8] - The total length of operational rail lines reached 906 kilometers [9] - 47 major industrial projects worth over 1 billion yuan commenced construction [9] Environmental and Ecological Initiatives - The city implemented significant measures for ecological protection, including the construction of five waste resource treatment facilities [15] - New photovoltaic installations reached 2.14 million kilowatts [15] - The city received international wetland city certification [15] Government and Administrative Improvements - The government improved the business environment with 58 reform measures [18] - Over 628 million services were provided to enterprises [18] - The "one-stop" service success rate exceeded 90% [18]

编辑丨王多鱼 排版丨水成文 在肿瘤的发生发展过程中，抗原特异性 CD8 ⁺ T 细胞 的命运与功能分化，直接决定了免疫系统能否有效控 制肿瘤。在肿瘤微环境内，CD8 ⁺ T 细胞主要分化为两个关键亚群：具有自我更新和增殖潜能的 前体耗竭 T 细胞 （Tpex） ，以及具备强大即时杀伤能力但增殖受限的 终末耗竭 T 细胞 （Ttex） 。Tpex 细胞是响 应免疫检查点阻断治疗的"种子"细胞，而 Ttex 细胞则是直接攻击肿瘤的"主力军"。 然而，究竟是哪些关键因子在幕后推动并维持该细胞的分化与功能，这一直是肿瘤免疫领域的核心谜团。 202 6 年 2 月 6 日 ， 西湖大学 董晨 院士团队 （ 清华大学免疫研究所博士生 潘必睿 为该论文的第一作 者 ） 在 Journal of Experimental Medicine 期刊发表了题为 ： Zbtb32 promotes CD8 ⁺ T cell differentiation and function in cancer 的研究论文。 该研究 首次系统鉴定出转录因子 Zbtb32 是驱动 CD8 ⁺ T 细胞向 终末耗竭状态 分化并增强其抗肿瘤功能 的核 ...